Blurbs

Leerink Partners Keeps a Buy Rating on Biohaven Pharmaceutical Holding Co (BHVN)

In a report issued on February 27, Marc Goodman from Leerink Partners maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVNResearch Report), with a price target of $150.00. The company’s shares closed last Monday at $118.71.

According to TipRanks.com, Goodman is a 3-star analyst with an average return of 0.9% and a 45.6% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Intra-Cellular Therapies, and Satsuma Pharmaceuticals.

Currently, the analyst consensus on Biohaven Pharmaceutical Holding Co is a Strong Buy with an average price target of $158.43, implying a 32.7% upside from current levels. In a report issued on February 21, Mizuho Securities also maintained a Buy rating on the stock with a $144.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Biohaven Pharmaceutical Holding Co’s market cap is currently $8.19B and has a P/E ratio of -9.03.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Read More on BHVN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More